Valo Therapeutics Limited, a cancer immunotherapy company developing neoantigen-coated oncolytic viruses as therapeutic vaccines, announced today that it has named Dr Michael Stein as its new chief executive officer, after he served as part-time co-chairman since the company's January 2017inception.

Dr Stein's career has involved executive leadership and board roles with various University start-ups, most recently breaking the UK record for a seed round as CEO of OxStem. Another notable success includes the Map of Medicine, which Dr Stein co-founded with UCL in 2001, taking it from start-up to a multi-million-pound exit to Informa plc in 2005 before it was sold to Hearst Inc. in 2008, where he continued to serve as EVP (Healthcare Innovation) until 2011.

Valo Tx co-chairman, Matti Hautsalo commented: "We are excited that Michael is dedicating himself full time to Valo Tx. Michael is a highly experienced, international business leader who brings significant fundraising and partnering experience as well as immunological and medical expertise. We look forward to continuing to work with him to develop life changing treatments for cancer."